EG25039A - Process for preparation of compounds used for inhibition of one or more tyrosine kinases. - Google Patents

Process for preparation of compounds used for inhibition of one or more tyrosine kinases.

Info

Publication number
EG25039A
EG25039A EGNA2007001382A EG25039A EG 25039 A EG25039 A EG 25039A EG NA2007001382 A EGNA2007001382 A EG NA2007001382A EG 25039 A EG25039 A EG 25039A
Authority
EG
Egypt
Prior art keywords
inhibition
preparation
compounds used
tyrosine kinases
kinases
Prior art date
Application number
Other languages
English (en)
Inventor
Mckenna Joseph
Wen-Chung Shieh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of EG25039A publication Critical patent/EG25039A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
EGNA2007001382 2005-06-09 2007-12-09 Process for preparation of compounds used for inhibition of one or more tyrosine kinases. EG25039A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US70559005P 2005-08-04 2005-08-04
PCT/US2006/022155 WO2006135641A2 (en) 2005-06-09 2006-06-07 PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE

Publications (1)

Publication Number Publication Date
EG25039A true EG25039A (en) 2011-07-06

Family

ID=37091153

Family Applications (1)

Application Number Title Priority Date Filing Date
EGNA2007001382 EG25039A (en) 2005-06-09 2007-12-09 Process for preparation of compounds used for inhibition of one or more tyrosine kinases.

Country Status (32)

Country Link
US (2) US8124763B2 (ar)
EP (1) EP1924574B1 (ar)
JP (1) JP5118024B2 (ar)
KR (3) KR101514593B1 (ar)
AR (1) AR053890A1 (ar)
AT (1) ATE487709T1 (ar)
AU (1) AU2006258051B2 (ar)
BR (1) BRPI0611663A2 (ar)
CA (1) CA2610105C (ar)
CY (1) CY1111428T1 (ar)
DE (1) DE602006018156D1 (ar)
DK (1) DK1924574T3 (ar)
EC (1) ECSP077982A (ar)
EG (1) EG25039A (ar)
GT (1) GT200600217A (ar)
HK (1) HK1117524A1 (ar)
IL (1) IL187421A (ar)
JO (1) JO2636B1 (ar)
MA (1) MA29599B1 (ar)
MX (1) MX2007015423A (ar)
MY (1) MY147436A (ar)
NO (1) NO340743B1 (ar)
NZ (1) NZ563740A (ar)
PE (1) PE20070015A1 (ar)
PL (1) PL1924574T3 (ar)
PT (1) PT1924574E (ar)
RU (1) RU2444520C2 (ar)
SA (1) SA06270147B1 (ar)
SI (1) SI1924574T1 (ar)
TN (1) TNSN07463A1 (ar)
TW (1) TWI430999B (ar)
WO (1) WO2006135641A2 (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
EP2305667A3 (en) 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
JP5486012B2 (ja) 2008-11-05 2014-05-07 テバ ファーマシューティカル インダストリーズ リミティド ニロチニブＨＣｌ結晶形
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
EP2691539B1 (en) 2011-03-31 2018-04-25 The Procter and Gamble Company Methods for identifying and evaluating skin-active agents effective for treating dandruff
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
WO2019152977A2 (en) 2018-02-05 2019-08-08 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
AU5539294A (en) 1992-12-24 1994-07-19 Hemagen/Pfc Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
ATE216998T1 (de) 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
CA2461556A1 (en) 2001-10-15 2003-04-24 Crititech, Inc. Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
WO2003057128A2 (en) 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
FR2840303B1 (fr) 2002-05-31 2005-07-15 Rhodia Chimie Sa Procede d'arylation ou de vinylation ou d'alcylynation d'un compose nucleophile
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005042539A1 (en) 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
MXPA06006710A (es) 2003-12-17 2006-08-31 Bionumerik Pharmaceuticals Inc Formulaciones farmaceuticas de camptotecinas y proceso para su elaboracion.
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
TNSN07463A1 (en) 2009-03-17
KR101514593B1 (ko) 2015-04-22
KR20120066067A (ko) 2012-06-21
TWI430999B (zh) 2014-03-21
MX2007015423A (es) 2008-02-21
AR053890A1 (es) 2007-05-23
ECSP077982A (es) 2008-01-23
DK1924574T3 (da) 2011-02-14
EP1924574A2 (en) 2008-05-28
WO2006135641A2 (en) 2006-12-21
DE602006018156D1 (de) 2010-12-23
NO20080157L (no) 2008-01-09
KR20130118394A (ko) 2013-10-29
GT200600217A (es) 2007-03-28
TW200726756A (en) 2007-07-16
PL1924574T3 (pl) 2011-04-29
PE20070015A1 (es) 2007-02-06
RU2444520C2 (ru) 2012-03-10
WO2006135641A3 (en) 2007-03-29
KR20080022093A (ko) 2008-03-10
EP1924574B1 (en) 2010-11-10
CA2610105A1 (en) 2006-12-21
NZ563740A (en) 2011-03-31
NO340743B1 (no) 2017-06-12
CY1111428T1 (el) 2015-08-05
AU2006258051B2 (en) 2010-09-09
US20120116081A1 (en) 2012-05-10
KR101216249B1 (ko) 2012-12-28
IL187421A0 (en) 2008-02-09
MY147436A (en) 2012-12-14
IL187421A (en) 2011-11-30
RU2007148231A (ru) 2009-07-20
US8124763B2 (en) 2012-02-28
SI1924574T1 (sl) 2011-02-28
HK1117524A1 (en) 2009-01-16
US8946416B2 (en) 2015-02-03
MA29599B1 (fr) 2008-07-01
CA2610105C (en) 2014-03-25
US20080188656A1 (en) 2008-08-07
ATE487709T1 (de) 2010-11-15
PT1924574E (pt) 2011-02-08
JP5118024B2 (ja) 2013-01-16
AU2006258051A1 (en) 2006-12-21
SA06270147B1 (ar) 2009-12-22
JO2636B1 (ar) 2012-06-17
JP2008545786A (ja) 2008-12-18
BRPI0611663A2 (pt) 2010-09-28

Similar Documents

Publication Publication Date Title
EG25039A (en) Process for preparation of compounds used for inhibition of one or more tyrosine kinases.
HK1254663A1 (zh) 用於實體腫瘤的治療的布魯頓酪氨酸激酶的抑制劑
HK1199254A1 (en) Process for the preparation of aurora kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
AP3433A (en) Triazolopyridazines as tyrosine kinase modultors
WO2008011557A3 (en) Heteroaryl inhibitors of rho kinase
WO2006050109A3 (en) Novel kinase inhibitors
ZA200606152B (en) 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
WO2007087245A3 (en) Ret tyrosine kinase inhibition
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
AP2870A (en) Odcase inhibitors for the treatment of malaria
EP2040546A4 (en) TYROSINE KINASE INHIBITORS
IL190727A0 (en) Method of inhibiting flt3 kinase
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
HK1114374A1 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
ZA200900019B (en) Tyrosine kinase inhibitors
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
IL187895A0 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
PT1968996E (pt) Processo para a preparação de ferro-succinilcaseína
WO2008061108A3 (en) Phthalazine derivatives
WO2007014250A8 (en) Abl kinase inhibition
IL184997A0 (en) Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis
EP1951252A4 (en) INHIBITORS OF TYROSINE KINASES